The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia
Open accessAbstract
Aberrant signal transduction contributes substantially to leukemogenesis. The Janus kinase 1 (JAK1) gene encodes a cytoplasmic tyrosine kinase that noncovalently associates with a variety of cytokine receptors and plays a nonredundant role in lymphoid cell precursor proliferation, survival, and differentiation. We report that somatic mutations in JAK1 occur in individuals with acute lymphoblastic leukemia (ALL). JAK1 mutations were more prevalent among adult subjects with the T cell precursor ALL, where they accounted for 18% of cases, and were associated with advanced age at diagnosis, poor response to therapy, and overall prognosis. All mutations were missense, and some were predicted to destabilize interdomain interactions controlling the activity of the kinase. Three mutations that were studied promoted JAK1 gain of function and conferred interleukin (IL)-3–independent growth in Ba/F3 cells and/or IL-9–independent resistance to dexamethasone-induced apoptosis in T cell lymphoma BW5147 cells. Such effects were associated with variably enhanced activation of multiple downstream signaling pathways. Leukemic cells with mutated JAK1 alleles shared a gene expression signature characterized by transcriptional up-regulation of genes positively controlled by JAK signaling. Our findings implicate dysregulated JAK1 function in ALL, particularly of T cell origin, and point to this kinase as a target for the development of novel antileukemic drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
James, C., Ugo, V., Le Couédic, J.-P., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., et al. (2005) · Nature · doi:10.1038/nature03546 · Cited by 3,544
Self-citationLevine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J. P., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.023 · Cited by 2,993
Treatment of Acute Lymphoblastic Leukemia
Pui, C.-H., & Evans, W. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052603 · Cited by 1,976
Yeoh, E.-J., Ross, M. E., Shurtleff, S. A., Williams, W. K., Patel, D., Mahfouz, R., Behm, F. G., Raimondi, S. C., Relling, M. V., Patel, A., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00032-6 · Cited by 1,917
JAK-STAT Signaling: From Interferons to Cytokines
Schindler, C., Levy, D. E., & Decker, T. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.r700016200 · Cited by 1,258
The JAK-STAT Signaling Pathway: Input and Output Integration
Murray, P. J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.5.2623 · Cited by 1,179
Rodig, S. J., Meraz, M. A., White, J. M., Lampe, P. A., Riley, J. K., Arthur, C. D., King, K. L., Sheehan, K. C. F., Yin, L., Pennica, D., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81166-6 · Cited by 853
The protein tyrosine kinase JAK1 complements defects in interferon-α/β and -γ signal transduction
Müller, M., Briscoe, J., Laxton, C., Guschin, D., Ziemiecki, A., Silvennoinen, O., Harpur, A. G., Barbieri, G., Witthuhn, B. A., Schindler, C., et al. (1993) · Nature · doi:10.1038/366129a0 · Cited by 760
Yamaoka, K., Saharinen, P., Pesu, M., Holt, V. E., Silvennoinen, O., & O'Shea, J. J. (2004) · Genome Biology · doi:10.1186/gb-2004-5-12-253 · Cited by 635
Molecular Genetics of Acute Lymphoblastic Leukemia
Armstrong, S. A., & Look, A. T. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.047 · Cited by 362
Chiaretti, S., Li, X., Gentleman, R., Vitale, A., Vignetti, M., Mandelli, F., Ritz, J., & Foa, R. (2004) · Blood · doi:10.1182/blood-2003-09-3243 · Cited by 351
Self-citationSaharinen, P., & Silvennoinen, O. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205156200 · Cited by 318
Activating alleles of JAK3 in acute megakaryoblastic leukemia
Walters, D. K., Mercher, T., Gu, T.-L., O'Hare, T., Tyner, J. W., Loriaux, M., Goss, V. L., Lee, K. A., Eide, C. A., Wong, M. J., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.06.002 · Cited by 317
Demoulin, J.-B., Uyttenhove, C., Van Roost, E., Lestré, B. D., Donckers, D., Van Snick, J., & Renauld, J.-C. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4710 · Cited by 182
Self-citationLindauer, K., Loerting, T., Liedl, K. R., & Kroemer, R. T. (2001) · Protein Engineering, Design and Selection · doi:10.1093/protein/14.1.27 · Cited by 182
Zhu, Y., Zhao, W., Fu, J., Shi, J., Pan, Q., Hu, J., Gao, X., Chen, B., Li, J., Xiong, S.-M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2832 · Cited by 157
Ferrando, A. A., Neuberg, D. S., Dodge, R. K., Paietta, E. M., Larson, R. A., Wiernik, P. H., Rowe, J. M., Caligiuri, M. A., Bloomfield, C. D., & Look, A. T. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15542-6 · Cited by 155
Chen, M., Cheng, A., Candotti, F., Zhou, Y.-J., Hymel, A., Fasth, A. L., Notarangelo, L. D., & O’Shea, J. J. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.3.947-956.2000 · Cited by 152
Unexpected Effects of FERM Domain Mutations on Catalytic Activity of Jak3
Zhou, Y., Chen, M., Cusack, N., Kimmel, L. H., Magnuson, K. S., Boyd, J. G., Lin, W., Roberts, J. L., Lengi, A. J., Buckley, R. H., et al. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00398-7 · Cited by 143
Baldus, C. D., Burmeister, T., Martus, P., Schwartz, S., Gökbuget, N., Bloomfield, C. D., Hoelzer, D. F., Thiel, E., & Hofmann, W. K. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.1580 · Cited by 110
Radtke, S., Haan, S., Jörissen, A., Hermanns, H. M., Diefenbach, S., Smyczek, T., de Leur, H. S.-V., Heinrich, P. C., Behrmann, I., & Haan, C. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500822200 · Cited by 90
Giordanetto, F., & Kroemer, R. T. (2002) · Protein Engineering Design and Selection · doi:10.1093/protein/15.9.727 · Cited by 89
Interleukin-9 is a major anti-apoptotic factor for thymic lymphomas
Renauld, J., Vink, A., Louahed, J., & Snick, J. V. (1995) · Blood · doi:10.1182/blood.v85.5.1300.bloodjournal8551300 · Cited by 85
Self-citationMapping of a Region within the N Terminus of Jak1 Involved in Cytokine Receptor Interaction
Haan, C., Is’harc, H., Hermanns, H. M., de Leur, H. S.-V., Kerr, I. M., Heinrich, P. C., Grötzinger, J., & Behrmann, I. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106135200 · Cited by 70
The changing scene of adult acute lymphoblastic leukemia
Vitale, A., Guarini, A. R., Chiaretti, S., & Foà, R. (2006) · Current Opinion in Oncology · doi:10.1097/01.cco.0000245317.82391.1b · Cited by 47
Self-citationEmerging drugs for adult acute lymphoblastic leukaemia
Thomas, X. (2005) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.10.3.591 · Cited by 8
Cited by
The JAK/STAT signaling pathway: from bench to clinic
Hu, X., li, J., Fu, M., Zhao, X., & Wang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00791-1 · Cited by 2,633
Integrated genomic characterization of pancreatic ductal adenocarcinoma
Raphael, B. J., Hruban, R. H., Aguirre, A. J., Moffitt, R. A., Yeh, J. J., Stewart, C., Robertson, A. G., Cherniack, A. D., Gupta, M., Getz, G., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.007 · Cited by 2,019
“We found a GNAS mutation in three of ten KRAS wildtype samples (Figures 3A and 3B), as well as a known pathogenic activating mutation in JAK1 (R724H) (Flex et al., 2008).”
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia
Zhang, J., Ding, L., Holmfeldt, L., Wu, G., Heatley, S. L., Payne-Turner, D., Easton, J., Chen, X., Wang, J., Rusch, M., et al. (2012) · Nature · doi:10.1038/nature10725 · Cited by 1,596
“TEL/AML1 fusion resulting from a cryptic t(12;21) is the most commongenetic lesion inpediatric ALL and definesa subgroup ofpatientswithan excellent prognosis.”
BackgroundThe origin and evolution of mutations in acute myeloid leukemia
Welch, J. S., Ley, T. J., Link, D. C., Miller, C. A., Larson, D. E., Koboldt, D. C., Wartman, L. D., Lamprecht, T. L., Liu, F., Xia, J., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.023 · Cited by 1,575
Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion
Castro, F., Cardoso, A. P., Gonçalves, R. M., Serre, K., & Oliveira, M. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00847 · Cited by 1,224
Metadata
- Authors
- Flex, E., Petrangeli, V., Stella, L., Chiaretti, S., Hornakova, T., Knoops, L., Ariola, C., Fodale, V., Clappier, E., Paoloni, F., Martinelli, S., Fragale, A., Sanchez, M., Tavolaro, S., Messina, M., Cazzaniga, G., Camera, A., Pizzolo, G., Tornesello, A., Vignetti, M., Battistini, A., Cavé, H., Gelb, B. D., Renauld, J.-C., Biondi, A., Constantinescu, S. N., Foà, R., & Tartaglia, M.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2008-03-24
- Volume
- 205
- Issue
- 4
- Pages
- 751-758
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2130003099
- Cited by
- 334
- References
- 27
- FWCI
- 26.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.